(IN BRIEF) Evotec SE has made significant progress in its strategic partnership with Bristol Myers Squibb, focused on developing a molecular glue-based therapy pipeline. This success has led to $75 million in milestone payments to Evotec. The partnership, which began … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Bristol-Myers Squibb, Dr Cord Dohrmann, Evotec, Molecular Glue, partnership, sustainability, USA
(IN BRIEF) Evotec SE announces a partnership with Inserm, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic markers in obesity and metabolic diseases. The collaboration, centered around the ABOS/DIABOMICS study led by Lille University Hospital, … Read the full press release
Posted in Business, Education, Financial, France, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Dr Cord Dohrmann, Evotec, France, Inserm, Lille University Hospital, metabolic disease, Noémie Pellegrin, Obesity, partnership, Prof. Bart Staels, Prof. Francois Pattou, RESEARCH, sustainability
(IN BRIEF) Bayer and Evotec have updated their strategic collaboration to focus on developing precision treatments for cardiovascular diseases (CVDs). Leveraging Evotec’s expertise in disease modelling using human induced pluripotent stem cells (iPSCs), the collaboration aims to identify and validate … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Bayer, Cardiovascular Therapies, Dr Cord Dohrmann, Dr. Christian Rommel, Evotec, Juergen Eckhardt, partnership, sustainability
(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ), for the treatment of solid tumors. … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?